Medicure Inc. (CVE:MPH – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as C$1.47 and last traded at C$1.47, with a volume of 8512 shares. The stock had previously closed at C$1.30.
Medicure Trading Up 13.1%
The company has a current ratio of 0.97, a quick ratio of 1.28 and a debt-to-equity ratio of 6.02. The company has a fifty day moving average price of C$1.21 and a 200-day moving average price of C$1.15. The firm has a market cap of C$15.34 million, a price-to-earnings ratio of -2.04 and a beta of 0.44.
About Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Read More
- Five stocks we like better than Medicure
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
